Mechanism of arterial remodeling in chronic allograft vasculopathy

doi:10.1007/s11684-011-0149-3

Front Med

2011, Vol. 5

Issue (3) : 248-253 https://doi.org/10.1007/s11684-011-0149-3

REVIEW

Mechanism of arterial remodeling in chronic allograft vasculopathy

Qichang Zheng, Shanglong Liu, Zifang Song(

)

Department of Hepatobiliary Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China

Download: PDF(146 KB) HTML
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks

Abstract

Chronic allograft vasculopathy (CAV) remains a major obstacle for long-term survival of grafts even though therapeutic strategies have improved considerably in recent years. CAV is characterized by concentric and diffuse neointimal formation, medial apoptosis, infiltration of lymphocyte or inflammatory cells, and deposition of extracellular matrix both in arteries and veins. Recent studies have shown that stem cells derived from the recipient contribute to neointimal formation under the regulation of chemokines and cytokines. Arterial remodeling in allografts eventually causes ischemic graft failure. The pathogenesis is multi-factorial with both immunologic and non-immunological factors being involved. The immunological factors have been discussed extensively in other articles. This review focuses mainly on the arterial remodeling that occurs in 3 layers of vessel walls including intimal injury, accumulation of smooth muscle-like cells in the neointimal, medial smooth muscle cell apoptosis, adventitial fibrosis, and deposition of extracellular matrix.

Keywords transplantation chronic rejection neointimal immunology arterial remodeling allograft vasculopathy

Corresponding Author(s): Song Zifang,Email:zsong@hust.edu.cn

Issue Date: 05 September 2011

Cite this article:

Qichang Zheng,Shanglong Liu,Zifang Song. Mechanism of arterial remodeling in chronic allograft vasculopathy[J]. Front Med, 2011, 5(3): 248-253.

URL:

https://academic.hep.com.cn/fmd/EN/10.1007/s11684-011-0149-3
https://academic.hep.com.cn/fmd/EN/Y2011/V5/I3/248

Fig.1 Types of allograft vascular remodeling. (A) Medial apoptosis and vessel expansion; (B) Constrictive remodeling; (C) Intimal thickening.

1	Sayegh MH, Carpenter CB. Transplantation 50 years later—progress, challenges, and promises. N Engl J Med 2004; 351(26): 2761–2766 doi: 10.1056/NEJMon043418 pmid:15616214
2	Belperio JA, Weigt SS, Fishbein MC, Lynch JP 3rd. Chronic lung allograft rejection: mechanisms and therapy. Proc Am Thorac Soc 2009; 6(1): 108–121 doi: 10.1513/pats.200807-073GO pmid:19131536
3	Hathout E, Beeson WL, Kuhn M, Johnston J, Fitts J, Razzouk A, Bailey L, Chinnock RE. Cardiac allograft vasculopathy in pediatric heart transplant recipients. Transpl Int 2006; 19(3): 184–189 doi: 10.1111/j.1432-2277.2005.00255.x pmid:16441766
4	Religa P, Bojakowski K, Gaciong Z, Thyberg J, Hedin U. Arteriosclerosis in rat aortic allografts: dynamics of cell growth, apoptosis and expression of extracellular matrix proteins. Mol Cell Biochem 2003; 249(1-2): 75–83 doi: 10.1023/A:1024755210105 pmid:12956401
5	Yuan X, Paez-Cortez J, Schmitt-Knosalla I, D’Addio F, Mfarrej B, Donnarumma M, Habicht A, Clarkson MR, Iacomini J, Glimcher LH, Sayegh MH, Ansari MJ. A novel role of CD4 Th17 cells in mediating cardiac allograft rejection and vasculopathy. J Exp Med 2008; 205(13): 3133–3144 doi: 10.1084/jem.20081937 pmid:19047438
6	Joosten SA, van Kooten C, Paul LC. Pathogenesis of chronic allograft rejection. Transpl Int 2003; 16(3): 137–145 doi: 10.1111/j.1432-2277.2003.tb00277.x pmid:12664207
7	Hamano K, Bashuda H, Ito H, Shirasawa B, Okumura K, Esato K. Graft vasculopathy and tolerance: does the balance of Th cells contribute to graft vasculopathy? J Surg Res 2000; 93(1): 28–34 doi: 10.1006/jsre.2000.5967 pmid:10945940
8	Rose ML. Interferon-γ and intimal hyperplasia. Circ Res 2007; 101(6): 542–544 doi: 10.1161/CIRCRESAHA.107.160911 pmid:17872472
9	Vessie EL, Hirsch GM, Lee TD. Aortic allograft vasculopathy is mediated by CD8(+) T cells in Cyclosporin A immunosuppressed mice. Transpl Immunol 2005; 15(1): 35–44 doi: 10.1016/j.trim.2005.02.006 pmid:16223671
10	Wang CY, Aronson I, Takuma S, Homma S, Naka Y, Alshafie T, Brovkovych V, Malinski T, Oz MC, Pinsky DJ. cAMP pulse during preservation inhibits the late development of cardiac isograft and allograft vasculopathy. Circ Res 2000; 86(9): 982–988 pmid:10807871
11	Lawson C, Wolf S. ICAM-1 signaling in endothelial cells. Pharmacol Rep 2009; 61(1): 22–32 pmid:19307690
12	Rahmani M, Cruz RP, Granville DJ, McManus BM. Allograft vasculopathy versus atherosclerosis. Circ Res 2006; 99(8): 801–815 doi: 10.1161/01.RES.0000246086.93555.f3 pmid:17038650
13	Mehra MR. Contemporary concepts in prevention and treatment of cardiac allograft vasculopathy. Am J Transplant 2006; 6(6): 1248–1256 doi: 10.1111/j.1600-6143.2006.01314.x pmid:16686747
14	Waller J, Brook NR, Nicholson ML. Cardiac allograft vasculopathy: current concepts and treatment. Transpl Int 2003; 16(6): 367–375 doi: 10.1111/j.1432-2277.2003.tb00316.x pmid:12756523
15	Ramzy D, Rao V, Brahm J, Miriuka S, Delgado D, Ross HJ. Cardiac allograft vasculopathy: a review. Can J Surg 2005; 48(4): 319–327 pmid:16149368
16	Hu Y, Davison F, Zhang Z, Xu Q. Endothelial replacement and angiogenesis in arteriosclerotic lesions of allografts are contributed by circulating progenitor cells. Circulation 2003; 108(25): 3122–3127 doi: 10.1161/01.CIR.0000105722.96112.67 pmid:14656919
17	Der H, Kerekes G, Veres K, Szodoray P, Toth J, Lakos G, Szegedi G, Soltesz P. Impaired endothelial function and increased carotid intima-media thickness in association with elevated von Willebrand antigen level in primary antiphospholipid syndrome. Lupus 2007; 16(7): 497–503 doi: 10.1177/0961203307080224 pmid:17670848
18	Raichlin E, Kushwaha SS, Lennon RJ, Frantz RP, Edwards BS, Prasad A, Rihal CS, Lerman A. Features of cardiac allograft coronary endothelial dysfunction. Am J Cardiol 2009; 103(8): 1154–1158 doi: 10.1016/j.amjcard.2008.12.039 pmid:19361606
19	Kofler S, Petrakopoulou P, Nickel T, Weis M. Cardiac allograft endothelial dysfunction. Eur J Clin Pharmacol 2006; 62(Suppl 1): 79–82 doi: 10.1007/s00228-005-0011-0
20	Khazaei M, Moien-Afshari F, Laher I. Vascular endothelial function in health and diseases. Pathophysiology 2008; 15(1): 49–67 doi: 10.1016/j.pathophys.2008.02.002 pmid:18434105
21	Russell ME. Macrophages in chronic rejection and graft vasculopathy: a diverse and dynamic cell with myriad roles. Transplant Rev 1999; 13(3): 157–168 doi: 10.1016/S0955-470X(99)80074-3
22	Woywodt A, Schroeder M, Gwinner W, Mengel M, Jaeger M, Schwarz A, Haller H, Haubitz M. Elevated numbers of circulating endothelial cells in renal transplant recipients. Transplantation 2003; 76(1): 1–4 doi: 10.1097/01.TP.0000074569.65127.26 pmid:12865778
23	Lagaaij EL, Cramer-Knijnenburg GF, van Kemenade FJ, van Es LA, Bruijn JA, van Krieken JH. Endothelial cell chimerism after renal transplantation and vascular rejection. Lancet 2001; 357(9249): 33–37 doi: 10.1016/S0140-6736(00)03569-8 pmid:11197359
24	Timmermans F, Plum J, Y?der MC, Ingram DA, Vandekerckhove B, Case J. Endothelial progenitor cells: identity defined? J Cell Mol Med 2009; 13(1): 87–102 doi: 10.1111/j.1582-4934.2008.00598.x pmid:19067770
25	Metharom P, Caplice NM. Vascular disease: a new progenitor biology. Curr Vasc Pharmacol 2007; 5(1): 61–68 doi: 10.2174/157016107779317215 pmid:17266614
26	Liu CS, Wang SH, Metharom P, Caplice NM. Myeloid lineage of human endothelial outgrowth cells circulating in blood and vasculogenic endothelial-like cells in the diseased vessel wall. J Vasc Res 2009; 46(6): 581–591 doi: 10.1159/000226226 pmid:19571578
27	Zhang F, Tsai S, Kato K, Yamanouchi D, Wang C, Rafii S, Liu B, Kent KC. Transforming growth factor-β promotes recruitment of bone marrow cells and bone marrow-derived mesenchymal stem cells through stimulation of MCP-1 production in vascular smooth muscle cells. J Biol Chem 2009; 284(26): 17564–17574 doi: 10.1074/jbc.M109.013987 pmid:19406748
28	Reinders ME, Rabelink TJ, Briscoe DM. Angiogenesis and endothelial cell repair in renal disease and allograft rejection. J Am Soc Nephrol 2006; 17(4): 932–942 doi: 10.1681/ASN.2005121250 pmid:16481411
29	Ii M, Losordo DW. Transplant graft vasculopathy: a dark side of bone marrow stem cells? Circulation 2003; 108(25): 3056–3058 doi: 10.1161/01.CIR.0000108160.88358.65 pmid:14691018
30	Cailhier JF, Laplante P, Hébert MJ. Endothelial apoptosis and chronic transplant vasculopathy: recent results, novel mechanisms. Am J Transplant 2006; 6(2): 247–253 doi: 10.1111/j.1600-6143.2005.01165.x pmid:16426308
31	Kang DH, Kang SW, Jeong HJ, Kim YS, Yang CW, Johnson RJ. Transplant graft vasculopathy: an emerging target for prevention and treatment of renal allograft dysfunction. Yonsei Med J 2004; 45(6): 1053–1058 pmid:15627297
32	Mitchell RN. Allograft arteriopathy: pathogenesis update. Cardiovasc Pathol 2004; 13(1): 33–40 doi: 10.1016/S1054-8807(03)00108-X pmid:14761783
33	Sata M, Saiura A, Kunisato A, Tojo A, Okada S, Tokuhisa T, Hirai H, Makuuchi M, Hirata Y, Nagai R. Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat Med 2002; 8(4): 403–409 doi: 10.1038/nm0402-403 pmid:11927948
34	Mitchell RN, Libby P. Vascular remodeling in transplant vasculopathy. Circ Res 2007; 100(7): 967–978 doi: 10.1161/01.RES.0000261982.76892.09 pmid:17431198
35	Zhang LN, Wilson DW, da Cunha V, Sullivan ME, Vergona R, Rutledge JC, Wang YX. Endothelial NO synthase deficiency promotes smooth muscle progenitor cells in association with upregulation of stromal cell-derived factor-1alpha in a mouse model of carotid artery ligation. Arterioscler Thromb Vasc Biol 2006; 26(4): 765–772 doi: 10.1161/01.ATV.0000207319.28254.8c pmid:16456092
36	Libby P, Pober JS. Chronic rejection. Immunity 2001; 14(4): 387–397 doi: 10.1016/S1074-7613(01)00119-4 pmid:11336684
37	Ma X, Hibbert B, White D. Contribution of recipient-derived cells in allograft neointima formation and the response to stent implantation. PloS ONE 2008; 3: e189418365026 doi: 10.1371/journal.pone.0001894
38	Song ZF, Li W, Zheng QC, Shang D, Shu XG, Guan SM. The origin of neointimal smooth muscle cells in transplant arteriosclerosis from recipient bone-marrow cells in rat aortic allograft. J Huazhong Univ Sci Technolog Med Sci 2007; 27(3): 303–306 doi: 10.1007/s11596-007-0322-8 pmid:17641848
39	George J, Afek A, Abashidze A, Shmilovich H, Deutsch V, Kopolovich J, Miller H, Keren G. Transfer of endothelial progenitor and bone marrow cells influences atherosclerotic plaque size and composition in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol 2005; 25(12): 2636–2641 doi: 10.1161/01.ATV.0000188554.49745.9e pmid:16195475
40	Religa P, Grudzinska MK, Bojakowski K, Soin J, Nozynski J, Zakliczynski M, Gaciong Z, Zembala M, S?derberg-Nauclér C. Host-derived smooth muscle cells accumulate in cardiac allografts: role of inflammation and monocyte chemoattractant protein 1. PLoS ONE 2009; 4(1): e4187 doi: 10.1371/journal.pone.0004187 pmid:19142231
41	Schober A. Chemokines in vascular dysfunction and remodeling. Arterioscler Thromb Vasc Biol 2008; 28(11): 1950–1959 doi: 10.1161/ATVBAHA.107.161224 pmid:18818421
42	Sipkins DA, Wei X, Wu JW, Runnels JM, C?té D, Means TK, Luster AD, Scadden DT, Lin CP. In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment. Nature 2005; 435(7044): 969–973 doi: 10.1038/nature03703 pmid:15959517
43	Sackstein R, Merzaban JS, Cain DW, Dagia NM, Spencer JA, Lin CP, Wohlgemuth R. Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone. Nat Med 2008; 14(2): 181–187 doi: 10.1038/nm1703 pmid:18193058
44	Henschler R, Deak E, Seifried E. Homing of mesenchymal stem cells. Transfus Med Hemother 2008; 35(4): 306–312 doi: 10.1159/000143110 pmid:21512647
45	Currie M, Zaki AM, Nejat S, Hirsch GM, Lee TD. Immunologic targets in the etiology of allograft vasculopathy: endothelium versus media. Transpl Immunol 2008; 19(2): 120–126 doi: 10.1016/j.trim.2008.03.002 pmid:18503887
46	Han CI, Campbell GR, Campbell JH. Circulating bone marrow cells can contribute to neointimal formation. J Vasc Res 2001; 38(2): 113–119 doi: 10.1159/000051038 pmid:11316947
47	Hart-Matyas M, Nejat S, Jordan JL, Hirsch GM, Lee TD. IFN-γ and Fas/FasL pathways cooperate to induce medial cell loss and neointimal lesion formation in allograft vasculopathy. Transpl Immunol 2010; 22(3-4): 157–164 doi: 10.1016/j.trim.2009.10.004 pmid:19895889
48	Karshovska E, Schober A. Mechanisms of arterial remodeling and neointima formation: an updated view on the chemokine system. Drug Discov Today Dis Mech 2008; 5(3-4): 293–298 doi: 10.1016/j.ddmec.2008.10.003
49	van Oostrom O, Fledderus JO, de Kleijn DP, Pasterkamp G, Verhaar MC. Smooth muscle progenitor cells: friend or foe in vascular disease? Curr Stem Cell Res Ther 2009; 4(2): 131–140 doi: 10.2174/157488809788167454 pmid:19442197
50	Eisen H, Kobashigawa J, Starling RC, Valantine H, Mancini D. Improving outcomes in heart transplantation: the potential of proliferation signal inhibitors. Transplant Proc 2005; 37(Suppl 4): 4–17 doi: 10.1016/j.transproceed.2005.02.118 pmid:15809102
51	Xu Q. Stem cells and transplant arteriosclerosis. Circ Res 2008; 102(9): 1011–1024 doi: 10.1161/CIRCRESAHA.108.171488 pmid:18467640
52	Jevon M, Dorling A, Hornick PI. Progenitor cells and vascular disease. Cell Prolif 2008; 41(Suppl 1): 146–164 doi: 10.1111/j.1365-2184.2008.00488.x pmid:18181954
53	Sartore S, Chiavegato A, Faggin E, Franch R, Puato M, Ausoni S, Pauletto P. Contribution of adventitial fibroblasts to neointima formation and vascular remodeling: from innocent bystander to active participant. Circ Res 2001; 89(12): 1111–1121 doi: 10.1161/hh2401.100844 pmid:11739275
54	G?ssl M, Lerman A. Endothelin: beyond a vasoconstrictor. Circulation 2006; 113(9): 1156–1158 doi: 10.1161/CIRCULATIONAHA.105.609271 pmid:16520422
55	Gutterman DD. Adventitia-dependent influences on vascular function. Am J Physiol 1999; 277(4 Pt 2): H1265–H1272 pmid:10516160
56	Sun H, Lu X, Wu S, Sun W. The effects of C-reactive protein, interleukin-6, and tumor necrosis factor-α in rat allograft adventitial inflammation and allograft arteriosclerosis. Transplant Proc 2009; 41(9): 3909–3912 doi: 10.1016/j.transproceed.2009.06.190 pmid:19917410
57	Shimizu K, Mitchell RN. The role of chemokines in transplant graft arterial disease. Arterioscler Thromb Vasc Biol 2008; 28(11): 1937–1949 doi: 10.1161/ATVBAHA.107.161232 pmid:18802020
58	Khan R, Agrotis A, Bobik A. Understanding the role of transforming growth factor-beta1 in intimal thickening after vascular injury. Cardiovasc Res 2007; 74(2): 223–234 doi: 10.1016/j.cardiores.2007.02.012 pmid:17349984

[1]	Ling Wang, Lining Wang, Xing Fan, Wei Tang, Jiong Hu. Fludarabine and intravenous busulfan conditioning with post-transplantation cyclophosphamide for allogeneic peripheral stem cell transplantation for adult patients with lymphoid malignancies: a prospective single-arm phase II study[J]. Front. Med., 2021, 15(1): 108-115.
[2]	Lijuan Hu, Qi Wang, Xiaohui Zhang, Lanping Xu, Yu Wang, Chenhua Yan, Huan Chen, Yuhong Chen, Kaiyan Liu, Hui Wang, Xiaojun Huang, Xiaodong Mo. Positive stool culture could predict the clinical outcomes of haploidentical hematopoietic stem cell transplantation[J]. Front. Med., 2019, 13(4): 492-503.
[3]	Junjun Jia, Xinyao Tian, Jianwen Jiang, Zhigang Ren, Haifeng Lu, Ning He, Haiyang Xie, Lin Zhou, Shusen Zheng. Structural shifts in the intestinal microbiota of rats treated with cyclosporine A after orthotropic liver transplantation[J]. Front. Med., 2019, 13(4): 451-460.
[4]	Xiaodong Mo, Xiaohui Zhang, Lanping Xu, Yu Wang, Chenhua Yan, Huan Chen, Yuhong Chen, Wei Han, Fengrong Wang, Jingzhi Wang, Kaiyan Liu, Xiaojun Huang. Minimal residual disease-directed immunotherapy for high-risk myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation[J]. Front. Med., 2019, 13(3): 354-364.
[5]	Liya Ju, Caroline Suberbielle, Xiaofan Li, Nuala Mooney, Dominique Charron. HLA and lung transplantation[J]. Front. Med., 2019, 13(3): 298-313.
[6]	Xiaodong Mo, Xiaohui Zhang, Lanping Xu, Yu Wang, Chenhua Yan, Huan Chen, Yuhong Chen, Wei Han, Fengrong Wang, Jingzhi Wang, Kaiyan Liu, Xiaojun Huang. Interferon-α salvage treatment is effective for patients with acute leukemia/myelodysplastic syndrome with unsatisfactory response to minimal residual disease-directed donor lymphocyte infusion after allogeneic hematopoietic stem cell transplantation[J]. Front. Med., 2019, 13(2): 238-249.
[7]	Meng Lv, Yingjun Chang, Xiaojun Huang. Everyone has a donor: contribution of the Chinese experience to global practice of haploidentical hematopoietic stem cell transplantation[J]. Front. Med., 2019, 13(1): 45-56.
[8]	Chenyang Wang, Qiurong Li, Jieshou Li. Gut microbiota and its implications in small bowel transplantation[J]. Front. Med., 2018, 12(3): 239-248.
[9]	Fei Gao, Jingyu Chen, Dong Wei, Bo Wu, Min Zhou. Lung transplantation for bronchiolitis obliterans syndrome after allogenic hematopoietic stem cell transplantation[J]. Front. Med., 2018, 12(2): 224-228.
[10]	Xuying Pei, Xiangyu Zhao, Yu Wang, Lanping Xu, Xiaohui Zhang, Kaiyan Liu, Yingjun Chang, Xiaojun Huang. Comparison of reference values for immune recovery between event-free patients receiving haploidentical allografts and those receiving human leukocyte antigen-matched sibling donor allografts[J]. Front. Med., 2018, 12(2): 153-163.
[11]	Xinyao Tian, Zhe Yang, Fangzhou Luo, Shusen Zheng. Gut microbial balance and liver transplantation: alteration, management, and prediction[J]. Front. Med., 2018, 12(2): 123-129.
[12]	Lanping Xu,Huanling Zhu,Jianda Hu,Depei Wu,Hao Jiang,Qian Jiang,Xiaojun Huang. Superiority of allogeneic hematopoietic stem cell transplantation to nilotinib and dasatinib for adult patients with chronic myelogenous leukemia in the accelerated phase[J]. Front. Med., 2015, 9(3): 304-311.
[13]	Farhad Sahebjam,John M. Vierling. Autoimmune hepatitis[J]. Front. Med., 2015, 9(2): 187-219.
[14]	Yingchen Li,Guoheng Hu,Qilai Cheng. Implantation of human umbilical cord mesenchymal stem cells for ischemic stroke: perspectives and challenges[J]. Front. Med., 2015, 9(1): 20-29.
[15]	Lei Li,Yimei Liu,Tiancheng Luo,Jian Zhou,Yingyong Hou,Xizhong Shen,Jiyao Wang. Comprehensive treatment of acute-on-chronic liver failure in a patient with hepatitis B: a case report[J]. Front. Med., 2014, 8(2): 250-253.

Viewed

Full text

Abstract

Cited

Shared

Discussed